211 related articles for article (PubMed ID: 34783071)
1. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
2.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
3. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
4. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer.
Zuhlke KA; Johnson AM; Tomlins SA; Palanisamy N; Carpten JD; Lange EM; Isaacs WB; Cooney KA
Prostate; 2014 Jun; 74(9):983-90. PubMed ID: 24796539
[TBL] [Abstract][Full Text] [Related]
6. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C; Zhang MC; Manyam GC; Vykoukal JV; Fahrmann JF; Peng S; Wu C; Park S; Kondraganti S; Wang D; Robinson BD; Loda M; Barbieri CE; Yap TA; Corn PG; Hanash S; Broom BM; Pilié PG; Thompson TC
Clin Cancer Res; 2023 Nov; 29(21):4464-4478. PubMed ID: 37581614
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.
Pedrani M; Salfi G; Merler S; Testi I; Cani M; Turco F; Trevisi E; Tortola L; Treglia G; Di Tanna GL; Vogl U; Gillessen S; Theurillat JP; Pereira Mestre R
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38704358
[TBL] [Abstract][Full Text] [Related]
9. SPOP mutation leads to genomic instability in prostate cancer.
Boysen G; Barbieri CE; Prandi D; Blattner M; Chae SS; Dahija A; Nataraj S; Huang D; Marotz C; Xu L; Huang J; Lecca P; Chhangawala S; Liu D; Zhou P; Sboner A; de Bono JS; Demichelis F; Houvras Y; Rubin MA
Elife; 2015 Sep; 4():. PubMed ID: 26374986
[TBL] [Abstract][Full Text] [Related]
10. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract][Full Text] [Related]
11. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Prostate Cancer: An Updated Review.
Hatano K; Nonomura N
World J Mens Health; 2022 Jul; 40(3):368-379. PubMed ID: 34448375
[TBL] [Abstract][Full Text] [Related]
13. Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM.
Orme JJ; Mer G; Huang H
Mol Cell; 2023 Mar; 83(5):655-656. PubMed ID: 36868187
[TBL] [Abstract][Full Text] [Related]
14. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
[TBL] [Abstract][Full Text] [Related]
15. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U; Hussain M; Shore N; Fizazi K; Tombal B; Penson D; Saad F; Efstathiou E; Madziarska K; Steinberg J; Sugg J; Lin X; Shen Q; Sternberg CN
Eur J Cancer; 2021 Dec; 159():237-246. PubMed ID: 34784577
[TBL] [Abstract][Full Text] [Related]
16. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study.
Connor MJ; Genie MG; Gonzalez M; Sarwar N; Thippu Jayaprakash K; Horan G; Hosking-Jervis F; Klimowska-Nassar N; Sukumar J; Pokrovska T; Basak D; Robinson A; Beresford M; Rai B; Mangar S; Khoo V; Dudderidge T; Falconer A; Winkler M; Watson V; Ahmed HU
BMJ Open; 2021 Nov; 11(11):e048996. PubMed ID: 34794989
[TBL] [Abstract][Full Text] [Related]
17. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Spaner DE; Luo Y; Wang G; Gallagher J; Tsui H; Shi Y
Cancer Med; 2021 Dec; 10(24):8789-8798. PubMed ID: 34791813
[TBL] [Abstract][Full Text] [Related]
18. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
[TBL] [Abstract][Full Text] [Related]
19. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.
Schlack K; Krabbe LM; Rahbar K; Isenberg K; Semjonow A; Schrader AJ; Boegemann M
Transl Androl Urol; 2021 Oct; 10(10):3986-3999. PubMed ID: 34804841
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of staphylococci species and their antimicrobial-resistance among patients with wound infection in Ethiopia: a systematic review and meta-analysis.
Chelkeba L; Melaku T
J Glob Antimicrob Resist; 2022 Jun; 29():483-498. PubMed ID: 34801740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]